MAY 23, 2025

2025 Request for Proposals

GRIN2B Foundation is pleased to announce the availability of our seed grant program to encourage and support patient-oriented research on GRIN2B-Related Neurodevelopmental Disorder.

The program is open to applicants worldwide and will consist of one-year grants. We anticipate awarding up to 4 grants in 2025 in the amounts of $10,000 (2), $20,000 (1) and $50,000 (1). GRIN2B Foundation will cover 8% in indirect costs.

Grant Application Deadline: August 15th, 2025

Anticipated Award(s) Announcement: November-December 2025

APPLY HERE (https://bit.ly/GRIN2B-2025rfp)

From 2024 through Spring 2025, we partnered with Combined Brain (http://www.combinedbrain.org) to develop our first Strategic Research Plan (https://drive.google.com/file/d/1myG2Xlf6fpWWfSuk4eaJmiqUQuOhMiU4/view?usp=sharing). Thanks to the work done on our SRP, we have developed the following Research Priority Areas.

GRIN2B Foundation Research Priority Areas

Our research mission is to directly facilitate the development of treatments for GRIN2B Disorders through gaining a robust understanding of the natural history, biomarkers, and functional characterization of this condition with the goal of identifying specific therapeutic targets.. Examples are included below.

Natural History

- Synchronizing data between existing registries and natural history studies
- Incorporating data from clinical visits into the research natural history registry

Biomarkers

- Acquiring EEGs from patients and analyzing for biomarkers
- Biofluid biomarkers, including proteomics or metabolomics
- Determining prevalence and presentation of autonomic dysfunction, and applicability as a biomarker

Functional Characterization

- Reclassification of VUSs to determine eligibility for future clinical trials
- Characterizing gain/loss of function, to determine eligibility for future clinical trials
- Identifying genotype-phenotype correlations

Characterization of Animal Models

- Thoroughly characterizing existing mouse models that do not yet have the basis of data needed for treatment development
- Development of new mouse models, only if it can be justified that this new model will benefit the GRIN2B community in a way that an existing mouse model cannot.

Quality Improvement Related to GRIN2B

- Quality Improvement Projects
- PSDA Cycles to build consistency and efficacy across institutions.

Treatments

- Preclinical work necessary to bring a therapeutic to the clinic
- Clinical trials of new or existing (ex: L-serine, radiprodil) treatments

---

If you have any questions or concerns with the application process, please contact GRIN2B Foundation Program Manager, Ryan Barash at ryan.barash@grin2b.com.

by Liz Marfia-Ash

Liz Marfia-Ash is the President and Founder of GRIN2B Foundation. She lives just outside Chicago, Illinois with her husband and three children and is a very busy working Mom.

Research
